Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection.
Fournier
S
S
Dupont
B
B
Pialoux
G
G
Eliaszewicz
M
M
Gonzalez-Canali
G
G
Feuillie
V
V
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D018791:CD4 Lymphocyte Count; D003630:Daunorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004067:Digestive System Neoplasms / Q000188:drug therapy; D018450:Disease Progression; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes; D008175:Lung Neoplasms / Q000188:drug therapy; D012074:Remission Induction; D012514:Sarcoma, Kaposi / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy; D015996:Survival Rate
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008081:Liposomes; D003630:Daunorubicin